Europeiska unionen - engelska - EMA (European Medicines Agency)

mylan s.a.s - ambrisentan - hypertension, pulmonary - antihypertensives, - ambrisentan mylan is indicated for the treatment of pulmonary arterial hypertension (pah) in adult patients of who functional class (fc) ii to iii, including use in combination treatment. efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease.ambrisentan mylan is indicated for the treatment of pulmonary arterial hypertension (pah) in adult patients of who functional class (fc) ii to iii, including use in combination treatment. efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease.

Filippinerna - engelska - FDA (Food And Drug Administration)

zoetis philippines, inc.; distributor: zoetis philippines, inc. - organic acids , oxine copper , mannan oligosaccharide (mos) , hydrated sodium calcium alumino silicate (hscas) (vet.) - feed premix powder - formulation: each kilogram contains: propionic acid.............50 g benzoic acid................15 g acetic acid.................. 15 g sorbic acid...............8 g oxine copper. ............1 g mannan oligosaccharide.............................50 g hydrated sodium calcium alumino silicate.....861 g

Europeiska unionen - engelska - EMA (European Medicines Agency)

accord healthcare s.l.u. - sildenafil citrate - hypertension, pulmonary - urologicals - adultstreatment of adult patients with pulmonary arterial hypertension classified as who functional class ii and iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.paediatric populationtreatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease.

Europeiska unionen - engelska - EMA (European Medicines Agency)

viatris limited - sildenafil citrate - hypertension, pulmonary - urologicals - adultstreatment of adult patients with pulmonary arterial hypertension classified as who functional class ii and iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.paediatric populationtreatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease (see section 5.1).

Europeiska unionen - engelska - EMA (European Medicines Agency)

upjohn eesv - sildenafil - hypertension, pulmonary - urologicals - treatment of adult patients with pulmonary arterial hypertension classified as world health organization (who) functional class ii and iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.paediatric populationtreatment of paediatric patients aged one year to 17 years old with pulmonary arterial hypertension. efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease.revatio solution for injection is for the treatment of adult patients with pulmonary arterial hypertension who are currently prescribed oral revatio and who are temporarily unable to take oral therapy, but are otherwise clinically and haemodynamically stable.revatio (oral) is indicated for treatment of adult patients with pulmonary arterial hypertension classified as who functional class ii and iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.

Europeiska unionen - engelska - EMA (European Medicines Agency)

janssen-cilag international nv - bosentan (as monohydrate) - hypertension, pulmonary; scleroderma, systemic - other antihypertensives - treatment of pulmonary arterial hypertension (pah) to improve exercise capacity and symptoms in patients with world health organization (who) functional class iii. efficacy has been shown in:primary (idiopathic and familial) pah;pah secondary to scleroderma without significant interstitial pulmonary disease;pah associated with congenital systemic-to-pulmonary shunts and eisenmenger’s physiology.some improvements have also been shown in patients with pah who functional class ii.stayveer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital-ulcer disease.

Europeiska unionen - engelska - EMA (European Medicines Agency)

janssen-cilag international n.v.   - bosentan (as monohydrate) - scleroderma, systemic; hypertension, pulmonary - antihypertensives, - treatment of pulmonary arterial hypertension (pah) to improve exercise capacity and symptoms in patients with who functional class iii.efficacy has been shown in: , primary (idiopathic and familial) pah;, pah secondary to scleroderma without significant interstitial pulmonary disease;, pah associated with congenital systemic-to-pulmonary shunts and eisenmenger's physiology. , some improvements have also been shown in patients with pah who functional class ii. tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.,

Europeiska unionen - engelska - EMA (European Medicines Agency)

nova laboratories ireland limited - spironolactone - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension.neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5.1 and 5.2). 

Malta - engelska - Malta Medicines Authority

glaxo smithkline uk limited - benzoyl peroxide; clindamycin - gel - benzoyl peroxide 50 mg/g; clindamycin 10 mg/g - anti-acne preparations

Malta - engelska - Malta Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - benzoyl peroxide, hydrous, clindamycin phosphate - gel - clindamycin phosphate 10 mg/g benzoyl peroxide hydrous 50 mg/g - anti-acne preparations